METHODS OF NON-INVASIVE DIAGNOSTICS AND MONITORING OF URINARY BLADDER CANCER
Authors:
V. Vít; D. Pacík
Authors‘ workplace:
Urologická klinika FN Brno
Published in:
Urol List 2011; 9(3): 7-14
Overview
Initial treatment of urothelial carcinoma (TCC) is associated with high rate of disease recurrence andtendency to progression when recurring. TCC prevalence appears to be more significant (than disease incidence) due to the high rate of superficial lesions recurrence. Patients with TCC thus require careful and long-term monitoring. Currently the standard monitoring process includes cystoscopy, which is an invasive, time consuming and cost ineffective method, often very unpleasant for the patient. The author in his article deals with current methods of non-invasive diagnostics and monitoring of TCC patients from the point of view of replacing cystoscopy with other methods or prolonging the intervals between individual cystoscopy sessions. The author also evaluates available outcomes of the individual tests (sensitivity, specifity) enabling urothelial tumours detection based on urine analysis. The test includes detection of tumour specific antigens in urine, antigens on the surface of cell elements in urine or detection of genetic abnormalities on the subcellular level. In the final section the author describes his own experience with fluorescence hybridization in situ.
Key words:
urothelial carcinoma, non-invasive diagnostics, tumour markers
Sources
1. Jemal A, Murray T, Ward E et al. Cancer statistics, 2005. Cancer J Clin 2005; 55(1): 10–30.
2. www.svod.cz
3. Kruger S, Mess F, Bohle A et al. Numerical aberrations of chromosome 17 and the 9p21 locus are independent predictors of tumor recurrence in non-invasive transitional cell carcinoma of the urinary bladder. Int J Oncol 2003; 23(1): 41–48.
4. Lambl VD. Uber Harnblasenkrebs. Ein Betrag zur mikroskopischen Diagnostik am Krankenbette. Vierteljahrschr Prakt Heilk 1856; 49: 1–32.
5. Brown FM. Urine cytology. Is it still gold standard for screening? Urol Clin North Am 2000; 27(1): 25–37.
6. Ramakumar S, Bhuiyan J, Besse C et al. Comparison of screening methods in the detection of bladder cancer. J Urol 1999; 161(2): 388–394.
7. Lotan Y, Roehrborn CG. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results od a comprehensive literature review and meta-analyses. Urology 2003; 61(1): 109–118.
8. Marek J, Babjuk M, Smolová H et al. Onkologická cytologie moči v urologické praxi. Praha: ISV 1999: 1. vyd.
9. Murphy WM, Emerson LD, Chander R et al. Flow citometry versus urinary cytology in the evaluation of patiens with bladder cancer. J Urol 1986; 136(4): 815–819.
10. Cummings KB, Barone JG, Ward WS. Diagnosis and staging of bladder cancer. Urol Clin North Am 1992; 19(3): 455–465.
11. Planz B, Jochims E, Deix T et al. The role of urinary cytology for detection of bladder cancor. Eur J Surg Oncol 2005; 31(3): 304–308.
12. Moonen PM, Perlen P, Kiemeney LA et al. Quantitative cytology on bladder wash versus voided urine: a comparison of results. Eur Urol 2006; 49(6): 1044–1049.
13. Pardoll DM, Vogelstein B, Coffey DS. A fixed dite of NA replication in eucaryotic cells. Cell 1980; 19(2): 527.
14. Stampfer DS, Carpinito GA, Rodriguez-Villanueva J et al. Evaluation of NMP22 in the detection of transitional cell carcinoma in the bladder. J Urol 1998; 159(2): 394–398.
15. Chahal R, Darshane A, Browning AJ et al. Evaluation of the clinical value of urinary NMP22 as a marker in the screening an surveillance of transitional cell carcinoma of the urinary bladder. Eur Urol 2001; 40(4): 415–421.
16. Mian C, Lodde M, Haitel A et al. Comparison of the monoclonal UBC-ELISA test and the NMP22 ELISA test for the detection of urothelial cell carcinoma of the bladder. Urology 2000; 55(2): 223–226.
17. Kumar A, Kumar R, Gupta NP. Comparison of NMP22 BladderChek Test and Urine Cytology for the Detection of Reccurrent Bladder Cancor. Oxford Journal Medicine & Japanese Journal of Clinical Oncology 2005; 36(3): 172–175.
18. Casella R, Huber P, Blochlinger A et al. Diagnostic value of urinary nuclear matrix protein 22 (NMP22) in bladder cancer. J Urol 2000; 163(Suppl): 591A.
19. Zippe C, Pandrangi L, Agarwal A. NMP22 is a sensitive, cost-effective test on patient at risk for bladder cancer. J Urol 1999; 161(1): 62.
20. Grossmann H, Messing E, Soloway M et al. Detection of bladder cancer usány a point-of-care proteomic assay. JAMA 2006; 295(3): 299–305.
21. Raitanen MP, Marttila T, Kaasainen E et al. Sensitivity of human komplement factor H related protein (BTA stat) test and voided urine cytology in the diagnosis of bladder cancer. J Urol 2000; 163(6): 1689–1692.
22. Giannopoulos A, Manousakas T, Gounari A et al. Comparative evaluatuion of the diagnostic performance of the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors. J Urol 2001; 166(2): 470–475.
23. Babjuk M, Koštířová M, Mudra K et al. Qualitative and quantitative detection of urinary human complement factor H-related protein (BTA stat and BTA TRAK) and fragments of cytokeratins 8, 18 (UBC Rapid and UBC IRMA) as markers for transitional cell carcinoma of the bladder. Eur Urol 2002; 41(1): 34–39.
24. Quek P, Chin CM, Lim PH. The role of BTA stat in clinical praktice. Ann Acad Med Singapure 2002; 31(2): 212–216.
25. Raitanen MP, Kaasinen E, Lukkarinen O et al. Analysis of false-positive BTA stat test results in patiens followed up for bladder cancer. Urology 2001; 57(4): 680–684.
26. Gibanel R, Ribal MJ, Ballesta AM et al. BTA TRAK urine test increase the efficacy of cytology in the diagnosis of low-grade transitional cell carcinoma of the bladder. Anticancer Res 2002; 22(2B): 1157–1160.
27. Babjuk M, Pešl M, Soukup V et al. Využití kvantitativní detekce proteinu blízkého faktoru H konplementu (BTA TRAK) v moči ke sledování pacientů s Ta a T1 uroteliálními nádory močového měchýře. Ces Urol 2006; 3: 5–9.
28. Konety BR, Nguyen TS, Dhur R et al. Detection of bladder cancer using a novel nuclear matrix protein, BCLA-4. Clin Cancer Res 2000; 6(7): 2618–2622.
29. Getzenberg RH, Konety BR, Oeler TA et al. Bladder cancer-associated nuclear matrix proteins. Cancer Res 1996; 56(7): 1690–1694.
30. Ramakumar S, Bhuian J, Besse C et al. Comparison of screening methods in the detection of bladder cancer. J Urol 1999; 161(2): 388–394.
31. Tsihlias J, Grossmann HB. The utility of fibrin/fibrinogen degradation products in superficial bladder cancer. Urol Clin North Am 2000; 27(1): 39–46.
32. Lokeshwar V, Obek C, Pham HT et al. Urinary hyaluronic acid and hyaluronidase: Markers for bladder cancer detection and evaluation of grade. J Urol 2000; 163(1): 348–356.
33. Hartmann SH, Schroeder GL, Civantos F et al. Hyaluronic acid and hyaluronidase. 2 new bladder carcinoma markers. Urologe A 2001; 40(2): 121–126.
34. Southgate J, Harden P, Trejdosiewitz LK. Cytokeratin expression patterns in normal and malignant urothelium: A review of the biological and diagnostic complications. Histol Histopathol 1999; 14(2): 657–664.
35. Sanchez-Carbayo M, Herrero E, Megias L et al. Comparative sensitivity of urinary Cyfra 21-1, urinary bladder cancer antigen, tissue polypeptide antigen and NMP22 to detect bladder cancer. J Urol 1999; 162(6): 1951–1956.
36. Pariente JL, Bordenave L, Jakob A et al. Analytical and prospective evaluation of urinary cytokeratin 19 fragment in bladder cancer. J Urol 2000; 163(4): 1116–1119.
37. Nisman B, Barak V, Shapiro A et al. Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma. Cancer 2002; 94(11): 2914–2922.
38. Fernandez-Gomez J, Rodriguez-Martinez JJ, Barmadah SE et al. Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer. Eur Urol 2007; 51(5): 1267–1274.
39. Boman H, Hedelin H, Holmang S. Urine tissue-polypeptide-specific antigen (TPS) as a marker for bladder cancer. Scan J Urol Nephrol 2001; 35(4): 270–274.
40. Menendéz-López V, Galán JA, Fernández-Suárez A et al. Usefulness of tissue polypeptide antigen in the follow-up bladder cancer. Urology 2003; 62(2): 243–248.
41. Bantis A, Zissimopoulos A, Sountoulides P et al. Tissue polypeptide antigen in the follow-up of patiens with urinary bladder cancor compared with convention urine cytology. Hell J Nucl Med 2010; 13(3): 213–217.
42. Rotem D, Cassel A, Lindenfeld N et al. Urinary cytokeratin 20 as a marker for transitional cell carcinoma. Eur Urol 2000; 37(5): 601–604.
43. Babjuk M, Soukup V, Pešl M et al. Urinary cytology and quantitative BTA and UBC tests in surveillance of patiens with pTa pT1 bladder urothelial carcinoma. Urology 2008; 71(4): 718–722.
44. Mian C, Lodde M, Haitel A et al. Comparison of two qualitative assays, the UBC Rapid Test and the BTA Stat Test , in the diagnosis of urothelial cell carcinoma of the bladder. Urology 2000; 56(2): 228–231.
45. Rhyu MS. Telomers, telomerase, and immortality. J Natl Cancer Inst 1995; 87(12): 884.
46. Harley CB, Futcher AB, Greider CW. Telomers shorten during aging of human fibroblasts. Nature 1990; 345(6274): 458–460.
47. Landman J, Chang Y, Kavaler E et al. Sensitivity and specificity of NMP22, telomerase, and BTA in the detection of human bladder cancer. Urology 1998; 52(3): 398–402.
48. Rahat MA, Lahat N, Gazawi H et al. Telomerase activity in patients with transitional cell carcinoma: a preliminary study. Cancer 1999; 85(4): 919–924.
49. Piatyszek MA, Kim NW, Weinich SL et al. Detection of telomerase activity in human cells and tumors by a telomeric repeat amplification protocol (TRAP). Methods Cell Sci 1995; 17: 1.
50. Muller M, Heicappell R, Crause H et al. Diagnosis of bladder cancer by detecting different telomerase-subunits in urine. J Urol 1999; 161(Suppl): 588A.
51. Cassel A, Rahat MA, Lahat N et al. Telomerase aktivity and cytokeratin 20 as markers for the detection and follow up of transitional cell carcinoma: anfulfilled promise. J Urol 2001; 166(3): 841–844.
52. Sanchini MA, Gunelli R, Nanni O et al. Relevance of Urine Telomerase in the Diagnosis of Bladder Cancor. Jama 2005; 294(16): 2052–2056.
53. Bowles L, Bialkowska-Hobrzanska H, Bukala B et al. A prospective evaluation of the diagnostic and potential prognostic utility of urinary human telomerase reverse transcriptase mRNA in patients with bladder cancer. Can J Urol 2004; 11(6): 2438–2444.
54. Van der Aa MN, Zwarthoff EC, Steyerberg EW et al. Microsatellite analysis of voided-urine symplex for surveillance of low-grade non-muscle-invasicve urothelial carcinoma: feasibility and clinical utility in a prospective multicenter study (Cost-Effectiveness of Follow-up of Urinary Bladder Cancor trial /CEFUB/). Eur Urol 2009; 55(3): 659–667.
55. Berger AP, Pardon W, Stenzl A et al. Microsatellite alterations in human bladder cancer: detection of tumor cells in urine sediment and tumor tissue. Eur Urol 2002; 41(5): 532–539.
56. van Rhijn BW, Lurkin I, Kirkels WJ et al. Microsatellite analysis – DNA test in urine competes with cystoskopy in follow –up of superficial bladdre carcinoma: a phase II trial. Cancer 2001; 92(4): 768–775.
57. Wild PJ, Fuchs T, Stoehr R et al. Detection of urothelial bladder cancor cells in voided urine can be improved by a combination of cytology and stabdardized microsatellite analysis. Cancer Epidemiol Biomarkers Prev 2009; 18(6): 1798–1806.
58. Sagerman PM, Saigo PE, Scheinfield J et al. Enhanced detection of bladder cancer in urine cytology with Lewis X, M344 and 19A211 antigens. Acta Cytol 1994; 38(4): 517–523.
59. Li HX, Li M, Li CL et al. ImmunoCyt and cytokeratin 20 immunocytochemistry as adjunkt markers for urine cytologic detection of bladder cancor: a prospective study. Anal Quant Cytol Histol 2010; 32(1): 45–52.
60. Mian C, Pycha A, Wiener H et al. Immunocyt: a new tool for detecting transitional cell cancer of the urinary tract. J Urol 1999; 161(5): 1486–1489.
61. Lodde M, Mian C, Negri G et al. Role of uCyt+ in the detection and surveillance of urothelial carcinoma. Urology 2003; 61(1): 243–247.
62. Greene KL, Berry A, Konety BR. Diagnostic Utility of the ImmunoCyt/uCyt + Test in Bladder Cancer. Rev Urol 2006; 8(4): 190–197.
63. Miyake H, Eto H, Arakawa S et al. Over expression of CD44V8-10 in urinary exfoliated cells as an independent prognostic predictor in patiens with urotelial cancer. J Urol 2002; 167(3): 1282–1287.
64. Sheinfeld J, Reuter VE, Melamed MR et al. Enhanced bladder cancer detection with the Lewis X antigen as a marker of neoplastic transformation. J Urol 1990; 143(2): 285–288.
65. Golijanin D, Sherman Y, Shapiro A et al. Detection of bladder tumors by immunostaining of the Lewisx antigen in cells from voided urine. Urology 1995; 46(2): 173.
66. Sawczuk IS, Pickens CL, Vasa UR et al. DD23 Biomarker: a prospective clinical assessment in routine urinary cytology specimens from patiens being monitored for TCC. Urol Oncol 2002; 7(5): 185–190.
67. Gilbert SM, Veltri RW, Sawczuk A et al. Evaluation of DD23 as a marker for detection of recurrent transitional cell carcinoma of the bladde in patient with a history of bladder cancer. Urology 2003; 61(3): 539–543.
68. Smith SD, Wheeler MA, Plescia J et al. Urine detection of survivin and diagnosis of bladder cancer. JAMA 2001; 285(3): 324.
69. Pešl M, Babjuk M, Soukup V et al. Význam stanovení survivinu v moči pro neinvazivní diagnostiku uroteliálních karcinomů močového měchýře. Ces Urol 2010; 14(2): 99–103.
70. Hausladen DA, Wheeler MA, Altieri DC et al. Effect of intravesical treatment of transitional cell carcinoma with bacillus Calmette-Guérin and mitomycin C on urinary suvivin levels and outcome. J Urol 2003; 170(1): 230–234.
71. Halling KC, King W, Sokolova IA et al. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol 2000; 164(5): 1768–1775.
72. Sarosdy MF, Schellhammer P, Bílinsky G et al. Clinical evaluation of a multi-target fluorescence in situ hybridization assay for detection of bladder cancer. J Urol 2002; 168(5): 1950–1954.
73. Friedrich MG, Toma MI, Hellstern A et al. Comparison of multi-target fluorescence in situ hybridization in urine with other noninvasive tests for detecting bladder cancer. BJU Int 2003; 92(9): 911–914.
74. Srougi M, Gattas G, Leite KR et al. Increasing the FISH detection of urothelial bladder carcinoma —a Brazilian experience comparing BTA stat, hyaluronic acid and cytology in voided urine specimens. J Urol 2004; 171: 71A.
75. Komentovaný poster 1232, AUA Meeting, May 16, 2011.
76. Mengual L, Marin-Aguilera M, Ribal MJ et al. Clinical Utility of Fluorescent in situ Hybridisation for the Surveillance of Bladder Cancer Patients Treated with Bacillus Calmette-Guérin Therapy. European Urology 2007; 52(2): 752–759.
77. Skacel M, Fahmy M, Brainard JA et al. Multi-target fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol 2003; 169(6): 2101–2105.
78. Moonen PMJ, Merkx GFM, Perlen P et al. UroVysion Compared with Cytology and Quantitative Cytology in the Surveillance of Non-Muscle-Invasive Bladder Cancer. European Urology 2007; 51(1): 1275–1280.
79. Babjuk M, Oesterlinck W, Sylvester R et al. Guidelines on Non-muscle invasive Bladder Cancer (TaT1 and CIS).
Labels
Paediatric urologist UrologyArticle was published in
Urological Journal
2011 Issue 3
Most read in this issue
- ILEAL NEOBLADDER AND ITS VARIANTS
- INTRAVESICAL INSTILLATION THERAPY IN THE TREATMENT OF SUPERFICIAL BLADDER CARCINOMA
- Treatment of muscle-invasive and metastatic bladder cancer – update of the EAU Guidelines
- METHODS OF NON-INVASIVE DIAGNOSTICS AND MONITORING OF URINARY BLADDER CANCER